Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) EBIT Margin (2016 - 2025)

Vistagen Therapeutics' EBIT Margin history spans 9 years, with the latest figure at 6450.83% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 1071.0% to 6450.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 8847.85%, a 90243.0% decrease, with the full-year FY2025 number at 11517.08%, down 841360.0% from a year prior.
  • EBIT Margin hit 6450.83% in Q4 2025 for Vistagen Therapeutics, up from 7772.48% in the prior quarter.
  • Over the last five years, EBIT Margin for VTGN hit a ceiling of 96633.33% in Q1 2025 and a floor of 42802.56% in Q1 2022.
  • Historically, EBIT Margin has averaged 2049.0% across 5 years, with a median of 5901.1% in 2022.
  • Biggest five-year swings in EBIT Margin: tumbled -4139555bps in 2022 and later soared 10355955bps in 2025.
  • Tracing VTGN's EBIT Margin over 5 years: stood at 2943.85% in 2021, then crashed by -84bps to 5425.83% in 2022, then skyrocketed by 65bps to 1918.25% in 2023, then plummeted by -237bps to 6461.54% in 2024, then grew by 0bps to 6450.83% in 2025.
  • Business Quant data shows EBIT Margin for VTGN at 6450.83% in Q4 2025, 7772.48% in Q3 2025, and 6477.05% in Q2 2025.